Oncoinvent Announces First Patient Dosed in its Phase 2 Clinical Trial of Radspherin® in Ovarian Cancer Patients

Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced that the first patient has been dosed in its Phase 2 study of Radspherin® in patients with peritoneal carcinomatosis from ovarian

Sammanhang: ...The Phase 2 trial is a randomized controlled study designed to assess progression-free survival (PFS) in primary advanced ovarian cancer patients treated with Radspherin® following complete surgical resection and pre-operative chemotherapy....

Omnämnda personer: with Radspherin.